According to CoinMeta, Hanyu Pharmaceutical announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration regarding the clinical trial application for HY3003 tablets, with a total of 4 acceptance numbers. HY3003 tablets are part of the company's development of a triple receptor agonist oral formulation for GLP-1R / GIPR / GCGR, intended for indications such as weight loss, type 2 diabetes, and metabolic-related fatty hepatitis. The dosage forms are 10mg, 20mg, 40mg, and 60mg, and the registration category is classified as Class 1 chemical drugs. This acceptance of the clinical trial marks the official entry of this product into the clinical development phase. Subsequently, phase I, II phase, and III phase clinical trials must be completed and approved before it can be launched on the market.